United Therapeutics Corporation Proceeds from Sale and Maturity of Debt Securities, Available-for-sale
United Therapeutics Corporation (UTHR) reported Proceeds from Sale and Maturity of Debt Securities, Available-for-sale of $1.04 billion for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-10-28.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities · last filed 2020-10-28
- United Therapeutics Corporation proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2020-09-30 was $333.10M, a 76.99% increase year-over-year.
- United Therapeutics Corporation proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2020-06-30 was $256.90M, a 120.70% increase year-over-year.
- United Therapeutics Corporation proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2020-03-31 was $451.40M, a 43.80% increase year-over-year.
- United Therapeutics Corporation proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2019-12-31 was $361.60M, a 163.75% increase year-over-year.
- United Therapeutics Corporation proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2019 was $980.10M, a 213.83% increase from fiscal 2018.
- United Therapeutics Corporation proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2018 was $312.30M, a 1461.50% increase from fiscal 2017.
- United Therapeutics Corporation proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2017 was $20.00M.
| Period end | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 3 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 6 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 9 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2020-09-30 | $333.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $590.00M derived: sum of 2 quarters · filed 2020-10-28 | $1.04B 10-Q · filed 2020-10-28 | $1.40B derived: sum of 4 quarters · filed 2020-10-28 |
| 2020-06-30 | $256.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $708.30M 10-Q · filed 2020-07-29 | $1.07B derived: sum of 3 quarters · filed 2020-07-29 | $1.26B derived: sum of 4 quarters · filed 2020-10-28 |
| 2020-03-31 | $451.40M 10-Q · filed 2020-04-29 | $813.00M derived: sum of 2 quarters · filed 2020-04-29 | $1.00B derived: sum of 3 quarters · filed 2020-10-28 | $1.12B derived: sum of 4 quarters · filed 2020-10-28 |
| 2019-12-31 | $361.60M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $549.80M derived: sum of 2 quarters · filed 2020-10-28 | $666.20M derived: sum of 3 quarters · filed 2020-10-28 | $980.10M 10-K · filed 2020-02-26 |
| 2019-09-30 | $188.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $304.60M derived: sum of 2 quarters · filed 2020-10-28 | $618.50M 10-Q · filed 2020-10-28 | $755.60M derived: sum of 4 quarters · filed 2020-10-28 |
| 2019-06-30 | $116.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $430.30M 10-Q · filed 2020-07-29 | $567.40M derived: sum of 3 quarters · filed 2020-07-29 | $616.40M derived: sum of 4 quarters · filed 2020-07-29 |
| 2019-03-31 | $313.90M 10-Q · filed 2020-04-29 | $451.00M derived: sum of 2 quarters · filed 2020-04-29 | $500.00M derived: sum of 3 quarters · filed 2020-04-29 | $556.20M derived: sum of 4 quarters · filed 2020-04-29 |
| 2018-12-31 | $137.10M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $186.10M derived: sum of 2 quarters · filed 2020-02-26 | $242.30M derived: sum of 3 quarters · filed 2020-02-26 | $312.30M 10-K · filed 2020-02-26 |
| 2018-09-30 | $49.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $105.20M derived: sum of 2 quarters · filed 2019-10-30 | $175.20M 10-Q · filed 2019-10-30 | |
| 2018-06-30 | $56.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $126.20M 10-Q · filed 2019-07-31 | ||
| 2018-03-31 | $70.00M 10-Q · filed 2019-05-01 | |||
| 2017-12-31 | $20.00M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |